ABBV vs. JPM: AbbVie vs. JPMorgan Chase Stock Comparison

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas JPMorgan Chase (JPM) belongs to Financials (Banks) — their GICS classifications point to very different parts of the market.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: JPMorgan Chase (JPM) earns 18.01% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of JPMorgan Chase (JPM) at 34.59%, which keeps about the industry-typical share.

AbbVie (ABBV) reports operating margin of 39.59%; JPMorgan Chase (JPM) doesn’t report a comparable line — in Banks, funding costs sit inside the core business rather than below an operating line, so profitability is better judged on net margin or ROE.

Profitability Metrics

Growth

Both AbbVie (ABBV) at 8.57% and JPMorgan Chase (JPM) at 7.32% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) at -0.84% is around its peer norm for EPS growth, while JPMorgan Chase (JPM) at 1.37% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

AbbVie (ABBV) shows current ratio of 0.87; JPMorgan Chase (JPM) doesn’t get one — Banks balance sheets aren’t split into current and non-current buckets, so short-term liquidity there is judged through regulatory measures instead.

AbbVie (ABBV) has no debt-to-equity ratio value reported for this period; for JPMorgan Chase (JPM), debt-to-equity ratio isn’t a meaningful figure under the Banks industry convention — no peer-based comparison can be drawn.

Financial Strength Metrics

Dividends

JPMorgan Chase (JPM) at 1.82% pays an industry-typical yield; AbbVie (ABBV) at 2.40% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile JPMorgan Chase (JPM) reports 25.80%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both AbbVie (ABBV) at 50.05 and JPMorgan Chase (JPM) at 14.03 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

AbbVie (ABBV) shows P/S ratio of 7.80; for JPMorgan Chase (JPM) the multiple is skipped — in Banks, income is dominated by interest spread rather than a conventional revenue line, so pricing per dollar of sales loses meaning and book- or earnings-based multiples carry the comparison.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile JPMorgan Chase (JPM) reports 2.53, ranking against industry peers normally.

Valuation Metrics